← All agents | ← Research tracker
Sirolimus (low-dose Rapamycin)
PubChem entry
Evidence Summary
Evidence Level: Moderate
Mechanism: Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Related Conditions
Long COVID (no page yet)
Clinical Trials
2 trial(s) registered
NCT06960928: Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 PHASE3 RECRUITING
NCT04948203: Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis PHASE2 ACTIVE_NOT_RECRUITING
Key Studies / References